AtCor's pressure rises
Wednesday, 30 July, 2008
AtCor Medical Holdings [ASX: ACG] has recorded its best sales figures ever, totalling around $6.5 million in 2008.
This represents a 47 per cent increase over last year's sales.
The largest gain was in Europe, where sales increased by 59 per cent. In North America sales increased by 46 per cent, and rest of the world by eight per cent.
The company's main product, the SphygmoCor system, identifies the effects of reflected blood pressure in the central aortic pressure wave.
Last week, the company reported two contracts for a total of US$1.6 million for pharmaceutical company.
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
